Amgen gets quick appeal in CareFirst's US case over Enbrel
MLex Summary: Amgen was granted leave to immediately appeal in CareFirst's US case accusing it of unlawfully delaying competition for its drug Enbrel after Amgen’s motion to dismiss was denied. Amgen...To view the full article, register now.
Already a subscriber? Click here to view full article